2020 half year results

2020/09/16 - Financial public releases

Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis

2020 second quarter consolidated sales

2020/07/20 - Financial public releases

Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Divestment of US rights

2020/07/02 - Financial public releases

Virbac completes divestment of U.S. Rights to SENTINEL^® brands to MSD Animal Health

Signing of an agreement

2020/05/13 - Financial public releases

Virbac to divest U.S. Rights to SENTINEL^® brands to MSD Animal Health

2020 first quarter consolidated sales

2020/04/15 - Financial public releases

2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

2019 annual results

2020/03/16 - Financial public releases

2019 operating profit from ordinary activities on the rise

2019 Annual consolidated sales

2020/01/16 - Financial public releases

2019 annual revenue shows strong growth of +6.6% at constant exchange rates

The Group raises the 2019 annual outlook

2019/12/20 - Financial public releases

2019 third quarter consolidated sales

2019/10/11 - Financial public releases

Solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019

Stock exchange: Virbac again in the SBF 120

2019/09/19 - Financial public releases

Following the quarterly review of its indices, the Paris stock exchange operator, Euronext, includes Virbac in the CAC Mid 60 and SBF 120 as from 23 September.

2019 half year results

2019/09/16 - Financial public releases

Operating profit on the rise in the first half of 2019

Cyrille Petit appointed as a member of the Virbac supervisory board

2019/07/18 - Financial public releases

Cyrille Petit.jpg Virbac announces the arrival of Cyrille Petit as a member of the supervisory board as of June 18, 2019. In addition, on the audit committee he will replace Olivier Bohuon, who is also a member of the supervisory board.

2019 second quarter consolidated sales

2019/07/16 - Financial public releases

2019 first half-year revenue grew by +6.6% at constant exchange rates

2019 first quarter consolidated sales

2019/04/11 - Financial public releases

2019 first quarter revenue rose by +10.9% at comparable exchange rates

2018 annual results

2019/03/18 - Financial public releases

2018 operating profit from ordinary activities grew by 13.4%

2018 Annual consolidated sales

2019/01/17 - Financial public releases

2018 annual revenue grew by +4.5% at constant exchange rates

2018 third quarter consolidated sales

2018/10/11 - Financial public releases

Revenue grew by +5.5% at constant exchange rates at the end of September 2018

2018 half year results

2018/09/17 - Financial public releases

Operating profit up sharply in the first half of 2018

2018 second quarter consolidated sales

2018/07/17 - Financial public releases

Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018

2018 first quarter consolidated sales

2018/04/12 - Financial public releases

2018 first quarter revenue rose by +3.3% at comparable exchange rates

Webcast 2017 annual results

2018/03/19 - Financial public releases

2017 annual results

2018/03/14 - Financial public releases

Operating profit from ordinary activities 2017 comparable to 2016

2017 Annual consolidated sales

2018/01/16 - Financial public releases

Annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth

Aquaculture: Virbac postpones its option to buy Centrovet for three years

2017/11/22 - Financial public releases

By mutual agreement, Virbac and the other shareholders of Centrovet have decided to postpone the option to buy the Chilean aquaculture specialist for three years, under the same pricing conditions.

2017 third quarter consolidated sales

2017/10/12 - Financial public releases

Virbac: quarterly sales affected by distributor destocking in the United States

Virbac group: Solène Madelpuech joins the supervisory board

2017/09/22 - Financial public releases

On September 5, 2017, Virbac’s supervisory board co-opted Solène Madelpuech into the supervisory board as a new member. On the same day, Jeanine Dick, aged 81, announced her resignation.

2017 half year results

2017/09/11 - Financial public releases

Slight increase in first half results

2017 second quarter consolidated sales

2017/07/17 - Financial public releases

Virbac: second quarter sales growth largely offsets the decline in the first quarter

2017 first quarter consolidated sales

2017/04/12 - Financial public releases

First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States

2016 annual results

2017/03/13 - Financial public releases

Strong rebound in profitability in 2016

2016 Annual consolidated sales

2017/01/17 - Financial public releases

Annual sales growth of 4.5%, at constant exchange rates

St. Louis: lifting of the Warning Letter for the Virbac production site

2016/12/16 - Financial public releases

Virbac announces that it has received from the Food and drug administration (FDA) a communication confirming the lifting of the Warning Letter received in December 2015 for its St. Louis production site (Missouri, USA).

2016 third quarter consolidated sales

2016/10/13 - Financial public releases

Sales grow by 3.2% at the end of September at constant rates

2016 half year results

2016/09/19 - Financial public releases

Growth of half-year results

2016 second quarter consolidated sales

2016/07/18 - Financial public releases

Sales growth by 3.6% at constant exchange rates in the first half

2016 first quarter consolidated sales

2016/04/13 - Financial public releases

Sales in the first quarter 2016 : return to organic growth

2015 annual results

2016/03/14 - Financial public releases

2015 annual results heavily impacted by the United States

2015 Annual consolidated sales

2016/01/14 - Financial public releases

Annual sales growth of 10.2%, driven by exchange rates and acquisitions

2015 third quarter consolidated sales

2015/10/15 - Financial public releases

Virbac : sales grow by 5.5% in the third quarter

2015 half year results

2015/09/15 - Financial public releases

Half-year results heavily impacted by the United States

2015 second quarter consolidated sales

2015/07/16 - Financial public releases

Virbac : sales grow by 18.1% in the first half

Group's perspectives for 2015 impacted by the industrial situation in the United-States

2015/06/23 - Financial public releases

Group’s perspectives for 2015 impacted by the industrial situation in the United-States

2015 first quarter consolidated sales

2015/06/15 - Financial public releases

Sales growth of 17.1% in the first quarter

PEA-PME eligibility of Virbac

2015/03/24 - Financial public releases

Virbac, listed on Euronext Paris

2014 annual results

2015/03/16 - Financial public releases

Results grow in 2014 following a strong second half

2014 Annual consolidated sales

2015/01/15 - Financial public releases

Sustained growth in the fourth quarter

Virbac announces the closing of the SENTINEL^® brands family acquisition in the United States

2015/01/05 - Financial public releases

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL^® Flavor Tabs^® and SENTINEL^® SPECTRUM^®, marketed up to now by Novartis Animal Health.

Virbac agrees to acquire veterinary assets from Eli Lilly in the United States

2014/10/27 - Financial public releases

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

2014 third quarter consolidated sales

2014/10/16 - Financial public releases

Confirmation of the rebound of growth in the third quarter

2014 half year results

2014/08/29 - Financial public releases

Half-year results impacted by foreign exchange and the low level of activity in the United States

2014 second quarter consolidated sales

2014/07/17 - Financial public releases

Organic growth of 3% in the first half

Annual report 2013 available

2014/04/30 - Financial public releases

The annual report of the fiscal year ending at December 31, 2013 of Virbac is available:

download HERE (or in Investors > Financial reports > 2013);
or on request, under legal and regulatory conditions.

PEA-PME eligibility of Virbac

2014/04/23 - Financial public releases

Virbac, listed on Euronext Paris

2014 first quarter consolidated sales

2014/04/15 - Financial public releases

Organic growth of +4.3% in the first quarter

2013 annual results

2014/03/19 - Financial public releases

Current operating profit increases by 6.9% in 2013

2013 Annual consolidated sales

2014/01/16 - Financial public releases

Rebound of growth in the last quarter

2013 third quarter consolidated sales

2013/10/17 - Financial public releases

Slight rebound of organic growth in the third quarter

2013 half year results

2013/08/30 - Financial public releases

Slight increase of the current operating profit in the first half of 2013

2013 second quarter consolidated sales

2013/07/18 - Financial public releases

Sales growth of 9.4% in the second quarter

2013 first quarter consolidated sales

2013/04/16 - Financial public releases

Sales growth of 3.6% in the first quarter

2012 annual results

2013/03/11 - Financial public releases

A 15.8% net profit increase in 2012

2012 annual consolidated sales

2013/01/17 - Financial public releases

Sales growth of 11.5% in 2012

Virbac becomes a leader of the Aquaculture Health Market

2012/11/23 - Financial public releases

VIRBAC announces the signing on November 23d, 2012 of an agreement by which the Group is acquiring a majority stake in CENTROVET, the leader of the animal health market in Chile. This transaction will allow VIRBAC to become a key player in a fast-growing segment of the veterinary market: products used for protection and treatment in aquaculture breeding.

According to this agreement, VIRBAC has purchased 51% of the shares of the CENTROVET Group from its shareholders and will have the option to acquire the remaining capital stock at the end of a five year period. The transaction is effective as of the date of signing.

2012 third quarter consolidated sales

2012/10/18 - Financial public releases

Steady growth of sales in the third quarter

2012 half year results

2012/08/31 - Financial public releases

Strong growth of half-year earnings

2012 second quarter consolidated sales

2012/07/19 - Financial public releases

Continued solid sales growth in the second quarter

2012 acquisition

2012/06/25 - Financial public releases

Virbac acquires STOCKGUARD in New-Zealand

2012 first quarter consolidated sales

2012/04/18 - Financial public releases

Solid sales growth in the first quarter

Financial public releases

Products Finance Careers Press l All Virbac news

Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis

Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health

2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

2019 operating profit from ordinary activities on the rise

2019 annual revenue shows strong growth of +6.6% at constant exchange rates

Solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019

Operating profit on the rise in the first half of 2019

2019 first half-year revenue grew by +6.6% at constant exchange rates

2019 first quarter revenue rose by +10.9% at comparable exchange rates

2018 operating profit from ordinary activities grew by 13.4%

2018 annual revenue grew by +4.5% at constant exchange rates

Revenue grew by +5.5% at constant exchange rates at the end of September 2018

Operating profit up sharply in the first half of 2018

Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018

2018 first quarter revenue rose by +3.3% at comparable exchange rates

Operating profit from ordinary activities 2017 comparable to 2016

Annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth

By mutual agreement, Virbac and the other shareholders of Centrovet have decided to postpone the option to buy the Chilean aquaculture specialist for three years, under the same pricing conditions.

Virbac: quarterly sales affected by distributor destocking in the United States

Slight increase in first half results

Virbac: second quarter sales growth largely offsets the decline in the first quarter

First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States

Strong rebound in profitability in 2016

Annual sales growth of 4.5%, at constant exchange rates

Virbac announces that it has received from the Food and drug administration (FDA) a communication confirming the lifting of the Warning Letter received in December 2015 for its St. Louis production site (Missouri, USA).

Sales grow by 3.2% at the end of September at constant rates

Growth of half-year results

Sales growth by 3.6% at constant exchange rates in the first half

Sales in the first quarter 2016 : return to organic growth

2015 annual results heavily impacted by the United States

Annual sales growth of 10.2%, driven by exchange rates and acquisitions

Virbac : sales grow by 5.5% in the third quarter

Half-year results heavily impacted by the United States

Virbac : sales grow by 18.1% in the first half

Group’s perspectives for 2015 impacted by the industrial situation in the United-States

Sales growth of 17.1% in the first quarter

Virbac, listed on Euronext Paris

Results grow in 2014 following a strong second half

Sustained growth in the fourth quarter

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® Flavor Tabs® and SENTINEL® SPECTRUM®, marketed up to now by Novartis Animal Health.

Confirmation of the rebound of growth in the third quarter

Half-year results impacted by foreign exchange and the low level of activity in the United States

Organic growth of 3% in the first half

Current operating profit increases by 6.9% in 2013

Rebound of growth in the last quarter

Slight rebound of organic growth in the third quarter

Slight increase of the current operating profit in the first half of 2013

Sales growth of 9.4% in the second quarter

Sales growth of 3.6% in the first quarter

A 15.8% net profit increase in 2012

Sales growth of 11.5% in 2012

Virbac to divest U.S. Rights to SENTINEL^® brands to MSD Animal Health

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL^® Flavor Tabs^® and SENTINEL^® SPECTRUM^®, marketed up to now by Novartis Animal Health.